Logo Image
News
Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Media
Expert ConnectionsTranslating TrialsCase-Based Peer PerspectivesPodcastsVideosShorts
Conferences
Conference CoverageConference Listing
Publications
More
CME/CE
Continuing Education
Resources
Case-Based Digest Rx Road MapEventsAdvanced Practice Corner
Partners

Subscribe

  • News
  • Media
  • Conferences
  • Publications
  • CME/CE
  • Resources
  • Subscribe
  • Partners
  • Brain Cancer
  • Breast Cancer
    • Metastatic Breast Cancer
  • Gastrointestinal Cancer
    • Colorectal Cancer
    • Liver Cancer
    • Gastric Cancers
  • Genitourinary Cancer
    • Kidney Cancer
    • Bladder Cancer
    • Prostate Cancer
  • Gynecologic Cancers
    • Endometrial Cancer
    • Cervical Cancer
    • Ovarian Cancer
  • Head and Neck Cancers
  • Hematology
    • Leukemia
    • Graft-Vs-Host Disease
    • Myeloproliferative Neoplasms
    • Multiple Myeloma
    • Lymphoma
  • Lung Cancer
  • Pediatric Cancer
  • Sarcomas
  • Skin Cancer
    • Melanoma
Advertisement

Bobbie J. Rimel, MD

Advertisement

Articles by Bobbie J. Rimel, MD

Understanding the Adverse Events of PARP Inhibitors

ByBobbie J. Rimel, MD
February 23rd 2019

There are some adverse events that are common to all PARP inhibitors, and others that are specific to each drug.

Advertisement

Latest Updated Articles

  • Understanding the Adverse Events of PARP Inhibitors
    Understanding the Adverse Events of PARP Inhibitors

    February 23rd 2019



Advertisement
Advertisement

Trending on Oncology Nursing News

1

FDA Approves Imlunestrant Plus Abemaciclib for ESR1-Mutated, ER-Positive, HER2-Negative Advanced Breast Cancer

2

Prostate Cancer Care: ADT Management and APP Guidance

3

Oncology Experts Discuss On-Body Subcutaneous Isatuximab in Multiple Myeloma

4

Gynecologic Cancer Awareness: Dr. Teplinsky Discusses Nursing Roles

5

FDA Approves sNDA for Taletrectinib in ROS1+ NSCLC

  • About Us
  • Editorial Board
  • Contact Us
  • CancerNetwork.com
  • CureToday.com
  • OncLive.com
  • TargetedOnc.com
  • Advertise
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us